Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
25 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR PAVEL ADRIAN BORSCIOV
CENTRE MEDICO-CHIRURGICAL CLINIQUE DES ORMEAUX 36 RUE MARCEAU BP 70141, 76051 LE HAVRE CEDEX
CLINIQUE LES ORMEAUX
36 R MARCEAU, 76600 LE HAVRE
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical medicine · 2026
Objectives: The study examined tear and serum alterations using the ferning test and quantified the number of branches formed during the controlled drying of these biological fluids (tears and serum), in order to identify a potential diagnostic patterning test in individuals with obesity. Methods: A total of 61 patients aged between 25 and 72 years were enrolled (median age [interquartile range] = 39.0 [26] years). BMI values ranged from 19.1 to 47.5 kg/m2, with a median BMI (interquartile range) of 29.3 (12.1) kg/m2. Results: The Kruskal–Wallis test showed statistically significant differences among at least two Schirmer classes with respect to the number of branches observed in dried tears at a brightness threshold of 220 (H(2) = 8.485, p = 0.014). According to the Dunn post hoc test, Schirmer Class 1 showed a markedly lower number of branches compared with Classes 2 and 3 (p < 0.031 and p < 0.021), whereas no significant difference was found between Classes 2 and 3. The Kruskal–Wallis test further suggested the presence of statistically significant differences in the number of branches in dried serum, quantified using ImageJ2 at a brightness threshold of 190, across visceral fat classes (H(2) = 9.583, p = 0.008). Dunn’s post hoc tests revealed that the number of branches in serum analyzed at a brightness threshold of 190 was significantly higher in visceral fat class 3 compared to class 1 (pholm = 0.006), while no statistically significant differences were observed between classes 1 and 2 or between classes 2 and 3 (pholm > 0.05). Conclusions: In addition to other obesity-specific complications patients with obesity exhibit an increased risk of developing dry eye syndrome. The combined assessment of DPT in both the tear film and serum may represent a new method for analyzing obesity-associated biomarkers. Further studies are required to determine the sensitivity and specificity of these approaches in diagnosing systemic alterations induced by excess adipose tissue.
Frontiers in endocrinology · 2025
Background Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) represent a biologically heterogeneous tumor group that is increasingly recognized in adults but remains exceptionally rare in children. While adult management is guided by evidence-based recommendations, pediatric practice relies mainly on registry data and extrapolation. A direct comparison is needed to identify shared principles, highlight divergences, and define research priorities. Methods We performed a structured literature review of pediatric GEPNENs (pancreatic, gastrointestinal [excluding appendix], and neuroendocrine neoplasms of unknown primary) and contrasted these findings with adult guidelines (ENETS 2023–2024, ESMO 2020–2024, ASCO 2023, NANETS 2018-2023) and pivotal clinical trials. Domains analyzed included epidemiology, clinical presentation, histological and molecular characteristics, treatment strategies, outcomes, and guideline frameworks. Results Pediatric GEPNENs are strongly enriched for hereditary cancer predisposition syndromes (MEN1, VHL, NF1, TSC) and show a predominance of well-differentiated NET G1–G2. In contrast, adults exhibit the full spectrum of NET G1–3 and NEC G3. Somatostatin receptor (SSTR) expression is frequent in both pediatric and adult NETs, supporting the use of somatostatin analogues (SSAs) and peptide receptor radionuclide therapy (PRRT) in advanced disease; SSTR expression declines with increasing grade. Surgical resection remains the only curative option in both populations, with pediatric practice prioritizing organ preservation and minimization of late effects. In adults, systemic therapy sequencing is structured by randomized trials, whereas pediatric use of systemic therapies is adapted case-by-case, with emerging but still limited evidence. Survival in localized pediatric NETs exceeds 90%, but remains poor in metastatic and high-grade disease, similar to adults. Conclusions Although histological frameworks are shared, pediatric GEPNENs differ from adult disease in genetics, site distribution, functional status, and survivorship challenges. Adult evidence may be cautiously adapted to pediatrics, but pediatric-specific guidelines and collaborative research are urgently needed to address unique biological and clinical features and to harmonize long-term care.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Neuroendocrinology · 2026 · Journal Article
Barsch M, Gräßel L, Metzger P, von Werder A, et al.
Journal of medical virology · 2026 · Journal Article
Keskin S, Pavel STI, Sak R, Bahadori F, et al.
Journal of clinical medicine · 2026 · Journal Article
Ivanov G, Ilie M, Constantinescu G, Pavel C, et al.
Heart rhythm · 2026 · Journal Article
Wörmann J, Hausmann C, Bocchini Y, Fink T, et al.
Journal of parasitology research · 2026 · Journal Article
Mester P, Kunst C, Schmid S, Zimmermann K, et al.
Diagnostics (Basel, Switzerland) · 2026 · Journal Article
Anghel R, Folea AR, Moga VL, Pavel C, et al.
Journal of the American College of Surgeons · 2026 · Journal Article
Pavel MC, Mohedano A, Ferre A, Garcia-Huete L, et al.
PM & R : the journal of injury, function, and rehabilitation · 2026 · Letter
Viktor V, Ayra S, William P, Pavel K
Journal of clinical medicine · 2026 · Journal Article
Ganea CV, Alexa AI, Anton N, Sandu CA, et al.
European journal of nuclear medicine and molecular imaging · 2026 · Journal Article
Kwee RM, Pavel AM, Kwee TC
Chirurgia (Bucharest, Romania : 1990) · 2025 · Journal Article
Chipuc S, Troncota D, Pavel C, Bacalbasa N, et al.
Scientific reports · 2025 · Journal Article
Mester P, Pavel V, Stoeckert P, Müller M, et al.
Journal of clinical medicine · 2025 · Journal Article
Dascalu RI, Ilie M, Turculet CS, Popa BV, et al.
The Journal of arthroplasty · 2026 · Journal Article
Kashir I, Shanthanna H, Khanna V, Mbuagbaw L, et al.
Clinical pharmacology and therapeutics · 2026 · Journal Article
Sponfeldner MI, Dürr P, Lensker P, Gessner K, et al.
Journal of inflammation research · 2026 · Journal Article
Pavel V, Mester P, Höring M, Krautbauer S, et al.
Frontiers in endocrinology · 2025 · Journal Article
Kuhlen M, Claus R, Pavel ME, Kunstreich M, et al.
Life (Basel, Switzerland) · 2025 · Journal Article
Hrițcu LD, Boghian V, Pavel G, Hrițcu TD, et al.
Nutrients · 2025 · Journal Article
Bogdănici CG, Bogdănici CM, Pavel IA, Ganea CV, et al.
Disability and rehabilitation. Assistive technology · 2026 · Journal Article
Alves MJ, Orsi Medola F, Paschoarelli LC, Pavel N, et al.
Frontiers in endocrinology · 2025 · Journal Article
Kuhlen M, Claus R, Pavel ME, Kunstreich M, et al.
Clinical pharmacology and therapeutics · 2026 · Journal Article
Sponfeldner MI, Dürr P, Lensker P, Gessner K, et al.
International ophthalmology · 2025 · Journal Article
Sansome S, Banerjee U, Griffin B, Issa S, et al.
Case reports in surgery · 2026 · Journal Article
Trăilescu MD, Pavel AI, Crișan AS, Cindea CN, et al.
Journal of visualized experiments : JoVE · 2026 · Journal Article
Pavel A, Fernandes FA, Rose S, Fung C, et al.
Archives of osteoporosis · 2025 · Journal Article
N BV, A MS, A DR, H SG, et al.
Life (Basel, Switzerland) · 2025 · Journal Article
Hrițcu LD, Boghian V, Pavel G, Hrițcu TD, et al.
Health science reports · 2026 · Journal Article
Pavel MA, Lily SA, Monira S, Islam S, et al.
✨ Profil synthétique
IA · 26/05/2026Le Dr Pavel Adrian Borsciov est un rhumatologue exerçant à Le Havre. Ses publications sur PubMed couvrent divers sujets, notamment l'épidémiologie, la pédiatrie et l'imagerie ostéo-articulaire. Il a également publié des études de cas et des analyses de données du monde réel.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.